Phio Pharmaceuticals (PHIO) CEO Bitterman received 250,000 shares
Insider transactions reported
Robert J Bitterman (Chairman, Pres. & CEO at Phio Pharmaceuticals Corp., PHIO) reported that they received 250,000 shares, and gave up 4,111 shares at $2.32 to cover taxes or an exercise price on Sep 11, 2025. After these transactions the filing shows 271,421 shares held directly.
- Reporting person
- Bitterman Robert J
- Role
- Chairman, Pres. & CEO
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Sep 11, 2025 | Shares withheld for taxes or exercise price (F) | Common Stock, $.0001 par value1 | -4,111 | $2.32 | $9,538 | 21,421 direct |
| Sep 11, 2025 | Grant or award (A) | Common Stock, $.0001 par value2, 3 | +250,000 | - | - | 271,421 direct |
Holdings before and after
- Common Stock, $.0001 par value: 25,532 to 271,421 direct
Footnotes from the filing
- 1. The transaction represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting of restricted stock units. No shares were sold.
- 2. Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant.
- 3. Includes shares of common stock underlying unvested restricted stock units.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
- Shares withheld for taxes or exercise price:
- Code F marks shares handed back or withheld to pay taxes or an exercise price. No sale happens in the market.
FAQ
What did Bitterman report in this PHIO Form 4?
Robert J Bitterman (Chairman, Pres. & CEO at Phio Pharmaceuticals Corp., PHIO) reported that they received 250,000 shares, and gave up 4,111 shares at $2.32 to cover taxes or an exercise price on Sep 11, 2025. After these transactions the filing shows 271,421 shares held directly.
How many PHIO shares does Bitterman hold after this filing?
The filing shows 271,421 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for PHIO
Earlier insider filings at PHIO
- Jun 11, 2025Chairman, Pres & CEO Bitterman Robert J bought $4,840 worth of shares (2,000 units at $2.42), increasing direct ownership by 8% to 27,149 units (SEC Form 4)
- Jun 11, 2025Director Ferrara Robert L bought $6,050 worth of shares (2,500 units at $2.42), increasing direct ownership by 19% to 15,666 units (SEC Form 4)
- Jun 10, 2025Chairman, Pres & CEO Bitterman Robert J bought $4,125 worth of shares (1,500 units at $2.75), increasing direct ownership by 6% to 25,149 units (SEC Form 4)
- May 23, 2025Chairman, Pres & CEO Bitterman Robert J bought $7,446 worth of shares (4,200 units at $1.77), increasing direct ownership by 22% to 23,649 units (SEC Form 4)
- May 21, 2025Director Ferrara Robert L bought $4,550 worth of shares (2,500 units at $1.82), increasing direct ownership by 23% to 13,166 units (SEC Form 4)
Keep researching PHIO
- PHIO insider tradesEvery buy and sale reported by Phio Pharmaceuticals Corp. officers, directors and large holders.
- What is Form 4?The SEC filing that reports a change in an insider's holdings, such as a purchase, sale, option exercise or grant, generally within two business days.
- Form 4 explainedForm 4 is the SEC filing that discloses when officers, directors and 10% owners buy or sell company stock, due within 2 business days. Learn every key field and code.
- Insider trading trackerThe latest insider buys and sales across every stock.
- PHIO earnings historyPast Phio Pharmaceuticals Corp. earnings releases, newest first.
- PHIO financial statementsRevenue, profit, cash flow and balance sheet from Phio Pharmaceuticals Corp.'s SEC filings.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Follow PHIO and get a push notification the moment its next story breaks.